Business Context and Reporting Period
Company: Cryomedical Sciences, Inc. (Note: Metadata referenced "BIOLIFE SOLUTIONS INC," but the filing text identifies the registrant as Cryomedical Sciences, Inc.)
Reporting Period: Quarter ended September 30, 1995 (Unaudited)
Business Overview: The Company researches, develops, manufactures, and markets products for hypothermic medicine, primarily the CMS AccuProbe(R) System for cryosurgery. The Company also recently received FDA 510(k) clearance for its CMS Urethral Warmer System.
Key Financial Metrics
| Metric | Q3 1995 | Q3 1994 |
|---|---|---|
| Sales & Other Revenues | $2,019,422 | $3,305,957 |
| Gross Profit | $1,111,900 | $1,686,104 |
| Gross Margin | 55% | 51% |
| Operating Loss | $(374,505) | $(494,328) |
| Net Loss | $(372,727) | $(483,787) |
| Net Loss Per Share | $(0.01) | $(0.02) |
| Cash & Equivalents (End of Period) | $1,083,696 | $2,359,303 |
| Working Capital | $3,339,488 | $3,775,893 (June 30, 1995) |
| Net Cash Used in Operating Activities | $(29,150) | $(48,524) |
Material Changes vs. Prior Period
- Revenue Decline: Sales decreased 39% year-over-year, driven by a drop in AccuProbe system sales (6 units vs. 10 units) and fewer accessory procedures. Management attributes this to the lack of formal Medicare reimbursement for urologic cryosurgery.
- Improved Margins: Gross margin improved to 55% from 51% due to ongoing cost reduction measures.
- Expense Reductions:
- Research and Development expenses fell 59% to $362,052 due to staffing reductions and suspension of outside research grants.
- Sales and Marketing expenses decreased 15% to $631,977.
- General and Administrative expenses decreased 12% to $492,376.
- Net Loss Improvement: Despite lower revenue, the net loss narrowed by approximately 23% to $372,727, primarily due to significant operating expense cuts.
Guidance, Outlook, Risks, and Contingencies
- Reimbursement Risk: The primary risk to future sales is the lack of uniform insurance reimbursement policies. Medicare currently considers urological cryosurgery investigational. Management believes this uncertainty significantly impacts sales growth.
- Liquidity Outlook: Management believes current cash and working capital are sufficient to fund operations for the next 12 months, contingent on sales levels. The Company plans to pursue short-term financing and potentially additional equity financing if necessary.
- Legal Settlement: The Company reached an agreement in principle to settle a stockholder class action suit for $100,000 in cash and $350,000 in stock (total $450,000). This amount was accrued as of June 30, 1995. The settlement is subject to court approval.
- Patent Litigation: Patent infringement litigation with competitor Cryogenic Technology Limited (CryoTech) and distributor Candela Laser Corporation was discontinued after CryoTech entered receivership and Candela agreed to stop using the allegedly infringing probes.
- Regulatory Update: On October 26, 1995, the Company received FDA 510(k) clearance for the CMS Urethral Warmer System.
Investor Verification Checklist
- Verify the status of the $450,000 class action settlement and whether court approval has been granted.
- Monitor developments regarding Medicare and private insurer reimbursement policies for urological cryosurgery, as this is the primary driver of revenue.
- Confirm the Company's ability to maintain liquidity without immediate equity dilution, given the projected operating losses.
- Review the impact of the newly cleared Urethral Warmer System on future sales of the AccuProbe System.
- Assess the sustainability of the 59% reduction in R&D spending and its long-term effect on product development.